Visit JCR Japan

Visit JCR Japan

Home
Who we are
Innovation
Pipeline
Patients & families
Our commitment
Partnerships
Investors & media
Our products
Contact us

Copyright 2025, JCR Pharmaceuticals Co., Ltd. All Rights Reserved

Notice of orphan drug designation for JR-446 for mucopolysaccharidosis type IIIB by European Commission (EC)

June 24, 2025

|In News

|By Chris Miller

Back to Newsroom

Sitemap
Compliance
Privacy policy
Global policy
Cookie policy
Cookie settings

Copyright 2025, JCR Pharmaceuticals Co., Ltd. All Rights Reserved

Privacy Preference Center

Privacy Preferences